Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer.
Peroxisome proliferator activated receptor-gamma (PPARgamma) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. PPARgamma is expressed at high levels in adipose tissue and plays a central role in adipocyte differentiation. Recent studies have implicated PPARgamma in the pathogenesis of several human malignancies. Here we review the evidence that PPARgamma contributes to prostate carcinogenesis and the potential for PPARgamma as a novel therapeutic target for prostate cancer.
Smith
Matthew R
MR
Massachusetts General Hospital, Boston 02114, USA. smith.matthew@mgh.harvard.edu
Kantoff
Philip W
PW
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002839:Chromans / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000502:physiology; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000009:adverse effects / Q000235:genetics / Q000502:physiology; D000077288:Troglitazone
D000970:Antineoplastic Agents; D002839:Chromans; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077288:Troglitazone